RhumbLine Advisers’s Innate Pharma IPHA Stock Holding History

RhumbLine Advisers’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.68K	Sell	4,719 -15	-0.3%	-$25	﹤0.01%	3918
2026 Q1	$6.06K	Sell	4,734 -470	-9%	-$767	﹤0.01%	3862
2025 Q4	$9.11K	Buy	5,204 +4,734	+1,007%	+$9.14K	﹤0.01%	3865
2025 Q3	$916	Hold	470	–	–	﹤0.01%	4027
2025 Q2	$822	Sell	470 -205	-30%	-$416	﹤0.01%	4051
2025 Q1	$1.2K	Hold	675	–	–	﹤0.01%	4019
2024 Q4	$1.25K	Buy	675 +470	+229%	+$883	﹤0.01%	4061
2024 Q3	$469	Hold	205	–	–	﹤0.01%	4123
2024 Q2	$397	Hold	205	–	–	﹤0.01%	4297
2024 Q1	$590	Hold	205	–	–	﹤0.01%	4181
2023 Q4	$574	Hold	205	–	–	﹤0.01%	4196
2023 Q3	$518	Hold	205	–	–	﹤0.01%	4230
2023 Q2	$643	Buy	+205	New	+$630	﹤0.01%	4312

Other funds holding IPHA

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SmartHarvest Portfolios Poulsbo, Washington $309M AUM

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

RhumbLine Advisers's IPHA Position: Q2 2026 in Review

RhumbLine Advisers reduced its Innate Pharma (IPHA) stake by 0.32% in Q2 2026, selling an estimated $25 and leaving 4,719 shares worth $8.68K. The position accounts for ﹤0.01% of the portfolio, ranked #3918.

RhumbLine Advisers first reported a position in IPHA in Q2 2023 and has held it in 13 quarters since. The position peaked at $9.11K in Q4 2025. 10 funds tracked by Wall St. Rank hold IPHA as of Q2 2026.

RhumbLine Advisers held 4,719 shares of Innate Pharma worth $8.68K as of Q2 2026.
RhumbLine Advisers sold 15 Innate Pharma shares in Q2 2026, an estimated $25.
Innate Pharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3918 holding.
RhumbLine Advisers first reported a position in Innate Pharma in Q2 2023 and has held it in 13 quarters since.
RhumbLine Advisers's Innate Pharma position peaked at $9.11K in Q4 2025.
10 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.